Thompson Siegel & Walmsley LLC Roivant Sciences Ltd. Transaction History
Thompson Siegel & Walmsley LLC
- $6.43 Billion
- Q4 2024
A detailed history of Thompson Siegel & Walmsley LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Thompson Siegel & Walmsley LLC holds 565,337 shares of ROIV stock, worth $5.99 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
565,337
Previous 513,632
10.07%
Holding current value
$5.99 Million
Previous $5.93 Million
12.84%
% of portfolio
0.1%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding ROIV
# of Institutions
331Shares Held
505MCall Options Held
573KPut Options Held
739K-
Qvt Financial LP New York, NY65.8MShares$697 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$658 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$507 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$467 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$375 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.47B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...